文献速递妇科

变革的正确时机:IVB期子宫内膜癌异质性报告及2023 FIGO分期标准改进风险分层的价值

The right time for change: A report on the heterogeneity of IVB endometrial cancer and improved risk-stratification provided by new 2023 FIGO staging criteria.
PubMed 文献 · Gynecol Oncol · 2023-06-13

这项回顾性研究分析了2014至2020年接受肿瘤细胞减灭术的88例IVB期子宫内膜癌(2009 FIGO标准)患者,发现多数术前未怀疑IVB期,细胞减灭程度和盆腔局限转移与预后显著相关,应用2023 FIGO标准后58%患者分期改变且无进展生存期差异显著。

要点

  • 63.6%的IVB期患者术前未被怀疑为IVB期病变。
  • 细胞减灭程度(p=0.0101)和盆腔局限转移(p=0.0149)是显著预后因素。
  • 应用2023 FIGO标准后58%患者分期改变,无进展生存期差异显著(p=0.0307)。

核心结论

  • IVB期子宫内膜癌(2009 FIGO标准)涵盖异质性人群,某些临床病理特征、肿瘤负荷和细胞减灭程度与结局相关。
  • 2023 FIGO分期标准显著提高了风险分层能力。

研究设计与样本

  • 回顾性综述2014至2020年接受肿瘤细胞减灭术的IVB期子宫内膜癌(2009 FIGO标准)患者,共纳入88例。
  • 记录人口学、临床病理因素和结局,通过影像、手术记录和病理报告确定疾病负荷和分布。
  • 按2023 FIGO分期标准重新分期,分类变量用χ2或Fisher精确检验比较,Kaplan-Meier曲线和log-rank检验比较生存结局。

主要发现

  • 88例患者中,63.6%术前未被怀疑为IVB期(2009 FIGO标准)病变。
  • 72%患者接受初次肿瘤细胞减灭术,其中12例(19%)为不满意减灭。
  • 中位无进展生存期(PFS)为12个月(95% CI 10-16个月),中位总生存期(OS)为38个月(95% CI 19-61个月)。
  • 细胞减灭程度(p=0.0101)和盆腔局限转移性疾病(p=0.0149)是显著预后因素,而远处转移与更差结局无关。
  • 在初次肿瘤细胞减灭术患者中,肿瘤沉积数量(p=0.0453)和直径(p=0.0192)与PFS相关。

关键数值与推荐

  • 细胞减灭程度与PFS显著相关(p=0.0101)。
  • 盆腔局限转移性疾病与PFS显著相关(p=0.0149)。
  • 初次肿瘤细胞减灭术患者中,肿瘤沉积数量与PFS相关(p=0.0453),直径与PFS相关(p=0.0192)。
  • 2023 FIGO分期标准下PFS差异显著(p=0.0307),OS趋势(p=0.0550)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to provide a contemporary report on stage IVB endometrial carcinoma (2009 FIGO criteria) and applied the 2023 FIGO staging criteria to this population. METHODS: Retrospective review of patients who underwent cytoreduction for stage IVB endometrial carcinoma (2009 FIGO criteria) from 2014 to 2020 was performed. Demographics, clinicopathologic factors, and outcomes were recorded. Disease burden and distribution were determined by imaging, operative notes, and pathology reports. Patients were re-staged according to 2023 FIGO staging criteria. Categorical variables were compared using χ2 or Fisher's exact test, and Kaplan-Meier curves compared survival outcomes using the log-rank test. RESULTS: Eighty-eight cases were included. Most patients (63.6%) were not suspected to have stage IVB (2009 FIGO criteria) disease prior to surgery. Seventy-two percent of patients underwent primary cytoreduction, and 12 (19%) were suboptimal. Median progression-free survival (PFS) was 12 months (95% CI 10-16 months), and median overall survival (OS) was 38 months (95% CI 19-61 months). Degree of cytoreduction (p = 0.0101) and pelvic-confined metastatic disease (p = 0.0149) were significant prognostic factors, while distant metastases were not associated with worse outcomes. For those patients who underwent primary cytoreduction, number (p = 0.0453) and diameter (p = 0.0192) of tumor deposits were associated with PFS. When 2023 FIGO staging criteria were applied, 58% of patients underwent change in stage, and 8% did not meet criteria for complete staging. PFS was significantly different based on 2023 FIGO staging (p = 0.0307); a trend in OS was also noted (p = 0.0550). CONCLUSION: Stage IVB endometrial carcinoma (2009 FIGO criteria) encompasses a diverse cohort of patients, where certain clinicopathologic features, tumor burden, and degree of cytoreduction are associated with outcomes. The 2023 FIGO staging criteria significantly improves our ability to risk-stratify patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Haight PJ, Riedinger CJ, Backes FJ, et al. The right time for change: A report on the heterogeneity of IVB endometrial cancer and improved risk-stratification provided by new 2023 FIGO staging criteria. Gynecol Oncol. 2023. PMID: 37321153. doi:10.1016/j.ygyno.2023.05.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。